Skip to main
GUTS

GUTS Stock Forecast & Price Target

GUTS Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 75%
Buy 0%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Fractyl Health Inc. is positioned positively in the market due to the substantial rise in prescriptions for GLP-1 drugs, which increased by 587% from 2019 to 2024, indicating a growing recognition of their effectiveness in treating obesity and type 2 diabetes. The company’s advancements in GLP-1 PGTx therapy have demonstrated superior outcomes in blood glucose and weight control compared to existing treatments, supported by positive data from the REMAIN-1 trial. Furthermore, the anticipated scalability of manufacturing capabilities suggests that Fractyl Health is well-equipped to meet increasing demand as its product pipeline progresses.

Bears say

Fractyl Health Inc. faces a significant cash burn issue, compounded by the potential challenges in securing sufficient capital for the continued development of its Revita and Rejuva platforms. Additionally, while the company reports some improvements in metabolic parameters among participants, concerns remain regarding the effectiveness of its therapies in light of T2D patients' gradual loss of β-cell function and impaired GLP-1 function which may impede insulin production. Ultimately, the company’s reliance on milestone revenue from partnerships and collaborations raises further uncertainties about its financial stability and ability to advance its therapeutic offerings.

GUTS has been analyzed by 4 analysts, with a consensus rating of Buy. 75% of analysts recommend a Strong Buy, 0% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fractyl Health Inc (GUTS) Forecast

Analysts have given GUTS a Buy based on their latest research and market trends.

According to 4 analysts, GUTS has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fractyl Health Inc (GUTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.